Clinical Trial Update: A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control [Phase 3]

View source ↗

Summary

A Phase 3 crossover trial compared indacaterol to tiotropium as an active control to evaluate lung function in patients with moderate to severe COPD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Indacaterol (Arcapta Neohaler) (Indacaterol)
• Tiotropium (Spiriva) (tiotropium)

Snippet

Sponsor: Novartis | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2011-08-17